We would love to hear your thoughts about our site and services, please take our survey here.
I would prefer a 7am RNS to watch the SP open with an explosion.
A 3pm RND will have a nice impact but a 7am will bring the hear from the off and like SNG, rise sharply to dizzy heights.
Ill take a pound a share but be happy once we are 20p plus on the first but of positive news
Nice to see the chat living up and new investors arriving.
While on the beach enjoying the sunshine and Catching up on Hemo Heaven.
Will the mother of all RNS land and crack open a bottle of champagne to celebrate or it maybe just another ****tail while the share price slowly moves up under the radar before Vlad drops his new.
Ill take a license agreement first and then followup with other news after the share rockets.
GLA
We are running out of days in August for Vlad to drop the mother of all RNS news, followed by another and another. You cant keep it all to yourself Vlad, your investors and believers need to see what wonderful outputs of all your years of work and belief in making life easier for a lot of sufferers and help in the fight against Covid.
As I am away for a week, today would be a great start to my holiday, so please drop before 1pm.
GLA
Any Positive RNS would be nice to push the SP upwards, this stock is so undervalued and in need of some news. Time is ticking on so many fronts and with other Pharma stocks, this has a lot of legs and potential.
I wouldn't mind a COVID update but something positive would be great.
To be in perspective here. if HEMO has a billion buyout, that equates to £2.30 per share and currently SNG with a billion buyout, its £6+ per share.
T-Cell buyouts are usually multiple Billions as a previous post said and therefore this share is totally undervalued in my view. As JHFH says, its a possible Golden Egg waiting to hatch.
Covid & Lilly announcements could see this jump to 50-70p, just like SNG.
Morning All,
Bonus RNS in my view as wasn't the updates those who have been here a while was expecting. I wouldn't be surprised i the COVID and Lilly announcements followed swiftly as Vlad does like to drop RNS quickly and August is running out of days for Collaboration news?
For me there is a number of facts that governments need to consider
1) sng is going to save lives
2) sng is going to prevent ongoing treatments for other health issues
3) economies cant survive without people shopping, working, driving, going pub etc etc, sng is a treatment
4) billions spent on propping up economies and they cant afford another 100bn, so sng for a fraction of that cost is a no brainer
5) a vaccine will work for a while before this mutates and then it has no effect, sng is the silver bullet
Richard and the team have said they dont have the manufacturing capabilities and there its down to a sale or a license agreement and as pharmas are happy to spend billions, i wouldnt be surprised to see it snapped up.
All shares are a gamble and my humble view is that this has so much potential, Im happy to stay for the long haul. I like what I have read, like that profile of those working on the pipeline and believe it can produce some amazing results.
The SP is quite static which is a change from a few weeks/months back where it would rise to 10-15p and then drop back as the Traders squeezed every penny of profit. That's not for me and I don't like the risk of being out when news drops and it flys.
The Board is better now that the rampers and de-rampers are not around and investors can share snippets and views.
Wishful thinking on behalf, with no news and the board as quiet as HEMO Mice, its a game of patience. Been here for 5 months and watched the spikes and lows, just kept topping up when I can hoping for that Big Announcement while other Pharmas continue to show the way.......frustrating but maintaining patience.
Following the US/J&J announcement, looking at the detail, we have an entity in Belgium and have a relationship with J&J. Wonder if we have any link.
"'We are scaling up production in the US and worldwide to deliver a SARS-CoV-2 vaccine for emergency use,' said Dr Paul Stoffels, chief science officer at Johnson & Johnson, in a statement. "
"The company recently began phase I clinical trials, testing safety and efficacy for a one-dose and two-dose jab, in the US and Belgium."
It appears if you hit Phase 1 on CAR-T, then the big boys look to acquire you and for some hefty sums as well. The IND-Enabling from the FDA is what will certainly spike a price hike if its dropped into a RNS but imagine it will be quickly followed with a Licence agreement or takeover.
Exciting times with HEMO pipeline